Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AZN 
AstraZeneca PLC ADR (AZN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: AZN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $93.25
1 Year Target Price $93.25
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.2% | Avg. Invested days 39 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 256.58B USD | Price to earnings Ratio 31.09 | 1Y Target Price 93.25 |
Price to earnings Ratio 31.09 | 1Y Target Price 93.25 | ||
Volume (30-day avg) 12 | Beta 0.17 | 52 Weeks Range 60.83 - 86.57 | Updated Date 11/2/2025 |
52 Weeks Range 60.83 - 86.57 | Updated Date 11/2/2025 | ||
Dividends yield (FY) 1.90% | Basic EPS (TTM) 2.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 1.14 | Actual - |
Profitability
Profit Margin 14.68% | Operating Margin (TTM) 24.12% |
Management Effectiveness
Return on Assets (TTM) 8.28% | Return on Equity (TTM) 19.67% |
Valuation
Trailing PE 31.09 | Forward PE 16.31 | Enterprise Value 285969080802 | Price to Sales(TTM) 4.54 |
Enterprise Value 285969080802 | Price to Sales(TTM) 4.54 | ||
Enterprise Value to Revenue 5.06 | Enterprise Value to EBITDA 16.98 | Shares Outstanding 3100519206 | Shares Floating 1543102500 |
Shares Outstanding 3100519206 | Shares Floating 1543102500 | ||
Percent Insiders - | Percent Institutions 16.5 |
Upturn AI SWOT
AstraZeneca PLC ADR
Company Overview
History and Background
AstraZeneca PLC ADR (AZN) was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It has grown through internal innovation and strategic acquisitions, becoming a leading global biopharmaceutical company.
Core Business Areas
- Oncology: Focuses on developing and commercializing cancer therapies across various tumor types.
- Cardiovascular, Renal & Metabolism (CVRM): Develops treatments for heart failure, chronic kidney disease, diabetes, and related conditions.
- Respiratory & Immunology: Offers solutions for asthma, COPD, and immune-mediated diseases.
- Rare Disease: Developing life saving treatments for rare diseases
Leadership and Structure
AstraZeneca is led by CEO Pascal Soriot. The organizational structure includes research & development, commercial operations, and corporate functions. The Board of Directors provides oversight.
Top Products and Market Share
Key Offerings
- Tagrisso: A targeted therapy for EGFR-mutated non-small cell lung cancer. Controls approx. 30% of EGFR lung cancer market. Competitors include Roche (Alecensa) and Boehringer Ingelheim (Giotrif).
- Farxiga/Forxiga: An SGLT2 inhibitor for type 2 diabetes and heart failure. Global sales around $4.4 billion in 2022. Competitors include Eli Lilly (Jardiance) and Johnson & Johnson (Invokana).
- Imfinzi: An immune checkpoint inhibitor used in lung cancer and other cancers. A major player in the immuno-oncology field with growing market share. Competitors include Merck (Keytruda) and Bristol-Myers Squibb (Opdivo).
- Enhertu: HER2-directed antibody drug conjugate for breast and other cancers. Being co-developed and commercialized with Daiichi Sankyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and intense competition. Key trends include personalized medicine, digital health, and increasing regulatory scrutiny.
Positioning
AstraZeneca is a major player in oncology, CVRM, and respiratory diseases, with a strong pipeline of innovative therapies and a growing presence in emerging markets.
Total Addressable Market (TAM)
The global pharmaceuticals market is valued at approximately $1.48 trillion in 2022. AstraZeneca is positioned to capture a significant portion of this market through its diverse product portfolio and R&D efforts.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Diversified product portfolio
- Global presence
- Established brand reputation
- Successful track record of acquisitions
Weaknesses
- High debt levels
- Dependence on key products
- Exposure to patent expirations
- Regulatory risks
- Vulnerability to biosimilar competition
Opportunities
- Expansion into emerging markets
- Development of personalized medicine
- Strategic partnerships and collaborations
- Growth in biologics and biosimilars
- Increased demand for innovative therapies
Threats
- Increasing competition
- Pricing pressures
- Regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- PFE
- NVS
- LLY
- BMY
Competitive Landscape
AstraZeneca competes with other large pharmaceutical companies based on product portfolio, R&D capabilities, and market presence. Its strength lies in oncology and cardiovascular diseases. However, smaller biotech companies are also becoming increasingly competitive with novel treatments and niche segments
Major Acquisitions
Alexion Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 39000
- Strategic Rationale: Expanded AstraZeneca's presence in rare diseases and enhanced its pipeline with innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: AstraZeneca has experienced moderate growth in recent years, driven by new product launches and acquisitions. However, growth has been impacted by patent expirations and competition.
Future Projections: Analysts project continued growth for AstraZeneca, driven by its strong pipeline and expansion into emerging markets. Revenue growth is estimated at 5-8% per year over the next 3-5 years.
Recent Initiatives: Recent initiatives include the acquisition of Alexion Pharmaceuticals, which expanded AstraZeneca's presence in rare diseases, and strategic collaborations to develop new therapies.
Summary
AstraZeneca is a strong player in the pharmaceutical industry, with a diverse product portfolio and a robust R&D pipeline. The company's focus on oncology and cardiovascular diseases is paying off, but it faces increasing competition and pricing pressures. The Alexion acquisition significantly expands their position in rare diseases. Strategic acquisitions and pipeline execution will be crucial for continued growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AstraZeneca Investor Relations
- SEC Filings
- Yahoo Finance
- Company Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AstraZeneca PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-05-12 | CEO & Executive Director Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 94300 | Website https://www.astrazeneca.com |
Full time employees 94300 | Website https://www.astrazeneca.com | ||
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.